Latest revenue
$53.5M
as of 2026-03-31
Latest net income
$-9.1M
as of 2026-03-31
Net margin
-16.9%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AKBA is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $251.4M
- Enterprise value
- $152.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 9.18×
- Dividend yield
- 0.0%
- 52-wk high
- $4.08
- 52-wk low
- $0.88
- Beta
- —
- Shares out
- 268.3M
5-year trend
What this company does
Item 1. Business Overview We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid-stage programs targeting rare kidney diseases and early-stage programs targeting kidney disease and non-kidney focused indications. We have established the Company as a leader in the kidney community and believe our cross-organizational expertise in kidney disease positions us for…
AI summary unavailable — showing raw filing excerpt
Generated from AKBA's filing dated 2026-02-26
Key risks
Table of Contents Item 1A. Risk Factors. We face a variety of risks and uncertainties in our business. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also become important factors that affect our business, reputation, results of operations, financial condition and stock price which can be materially and adversely affected. If any of the following risks occurs, our business, financial condition, financial statements, results of operations and future growth prospects could be materially and adversely affected. Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy We have incurred significant…
AI summary unavailable — showing raw filing excerpt
Generated from AKBA's filing dated 2026-02-26
Profitability
Operating margin
9.9%
131.6%Net margin
-2.3%
94.8%Return on equity
-16.4%
111.6%Return on assets
-1.4%
95.5%Leverage
Debt / equity
10.55×
292.2%Long-term debt / equity
1.48×
288.1%Debt / assets
91.3%
25.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $53.5M | -6.6% | $-9.1M | -248.1% | -16.9% |
Q4 2025 2025-12-31 | $57.6M | +23.9% | $-12.2M | +46.3% | -21.2% |
Q3 2025 2025-09-30 | $58.8M | +57.0% | $540.0K | +102.7% | 0.9% |
Q2 2025 2025-06-30 | $62.5M | +43.1% | $247.0K | +102.9% | 0.4% |
Q1 2025 2025-03-31 | $57.3M | +75.8% | $6.1M | +134.0% | 10.7% |
Q4 2024 2024-12-31 | $46.5M | — | $-22.8M | — | -49.0% |
Q3 2024 2024-09-30 | $37.4M | -11.0% | $-20.0M | — | -53.5% |
Q2 2024 2024-06-30 | $43.6M | -22.6% | $-8.6M | — | -19.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AKBA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$86.6K
Insider selling
$1.1M
Net activity
−$1.0M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AKBA
Institutional value
$65.5M
Total shares held
48.8M
Distinct holders
96
-70 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 18.7M | $26.0M | -625.2K (-3.2%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 11.2M | $15.5M | — | New |
| 3 | CITIGROUP INC | 2.9M | $4.0M | +418.4K (+17.2%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.2M | $3.1M | — | New |
| 5 | VANGUARD FIDUCIARY TRUST CO | 1.8M | $2.5M | — | New |
| 6 | JANE STREET GROUP, LLC | 1.5M | $2.0M | +765.1K (+110.6%) | Added |
| 7 | DIMENSIONAL FUND ADVISORS LP | 921.9K | $1.3M | -649.1K (-41.3%) | Trimmed |
| 8 | UBS Group AG | 769.5K | $1.1M | -102.1K (-11.7%) | Trimmed |
| 9 | Invesco Ltd. | 720.1K | $1.0M | +50.9K (+7.6%) | Added |
| 10 | BNP PARIBAS FINANCIAL MARKETS | 665.6K | $925.2K | -64.8K (-8.9%) | Trimmed |
| 11 | Bank of New York Mellon Corp | 650.9K | $904.7K | -16.1K (-2.4%) | Trimmed |
| 12 | LOS ANGELES CAPITAL MANAGEMENT LLC | 601.3K | $835.8K | +571.7K (+1931.0%) | Added |
| 13 | Nuveen, LLC | 596.6K | $829.3K | +3.6K (+0.6%) | Added |
| 14 | RHUMBLINE ADVISERS | 306.9K | $426.6K | -10.5K (-3.3%) | Trimmed |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 274.4K | $381.5K | -479.5K (-63.6%) | Trimmed |
| 16 | ALPS ADVISORS INC | 218.1K | $303.1K | +179 (+0.1%) | Added |
| 17 | SAPIENT CAPITAL LLC | 200.0K | $278.0K | +0 (+0.0%) | No change |
| 18 | Russell Investments Group, Ltd. | 196.6K | $273.2K | +2.8K (+1.5%) | Added |
| 19 | DEUTSCHE BANK AG\ | 189.5K | $263.4K | +24.8K (+15.1%) | Added |
| 20 | Wealthspire Advisors, LLC | 180.0K | $250.2K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AKBA's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.